Ascendis Pharma (ASND) Misses Q1 EPS by 11c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.58), EUR0.11 worse than the analyst estimate of (EUR1.47). Revenue for the quarter came in at EUR100.95 million versus the consensus estimate of EUR93.49 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Jannik Sinner says he will not compete at US Open due to injury
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group